Recent studies consider RDD a clonal neoplastic process, as approximately 1/3 of these patients harbor gene mutations involving the MAPK/ERK pathway, e.g., NRAS, KRAS, MAP2K1, and, rarely, the BRAF mutation. This evidence concerns the gene MAP2K1 and sinus histiocytosis with massive lymphadenopathy.